全文获取类型
收费全文 | 33067篇 |
免费 | 3176篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 334篇 |
儿科学 | 1081篇 |
妇产科学 | 638篇 |
基础医学 | 4636篇 |
口腔科学 | 426篇 |
临床医学 | 4045篇 |
内科学 | 7199篇 |
皮肤病学 | 773篇 |
神经病学 | 3527篇 |
特种医学 | 1059篇 |
外国民族医学 | 1篇 |
外科学 | 4844篇 |
综合类 | 271篇 |
一般理论 | 30篇 |
预防医学 | 2842篇 |
眼科学 | 400篇 |
药学 | 1922篇 |
中国医学 | 68篇 |
肿瘤学 | 2285篇 |
出版年
2023年 | 120篇 |
2022年 | 267篇 |
2021年 | 589篇 |
2020年 | 494篇 |
2019年 | 886篇 |
2018年 | 1010篇 |
2017年 | 820篇 |
2016年 | 837篇 |
2015年 | 1031篇 |
2014年 | 1250篇 |
2013年 | 1733篇 |
2012年 | 2060篇 |
2011年 | 2262篇 |
2010年 | 1440篇 |
2009年 | 1330篇 |
2008年 | 1953篇 |
2007年 | 2034篇 |
2006年 | 1972篇 |
2005年 | 2041篇 |
2004年 | 1952篇 |
2003年 | 1962篇 |
2002年 | 2025篇 |
2001年 | 349篇 |
2000年 | 282篇 |
1999年 | 340篇 |
1998年 | 408篇 |
1997年 | 376篇 |
1996年 | 300篇 |
1995年 | 336篇 |
1994年 | 278篇 |
1993年 | 263篇 |
1992年 | 194篇 |
1991年 | 205篇 |
1990年 | 181篇 |
1989年 | 142篇 |
1988年 | 165篇 |
1987年 | 169篇 |
1986年 | 151篇 |
1985年 | 145篇 |
1984年 | 157篇 |
1983年 | 124篇 |
1982年 | 178篇 |
1981年 | 175篇 |
1980年 | 158篇 |
1979年 | 106篇 |
1978年 | 104篇 |
1977年 | 97篇 |
1976年 | 78篇 |
1975年 | 73篇 |
1972年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
2.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
3.
Jean‐Franois Etter 《Addiction (Abingdon, England)》2019,114(12):2252-2256
4.
5.
6.
7.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
8.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
9.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
10.